2023 Impact Report
20 Years of Progress
Cure JM is proud to have invested $23 million in research for better juvenile myositis treatments, care, and support.
Our network of researchers spans the globe and we are proud to have:
- Reduced diagnosis time by 75%, from 12 months to 3 months
- Improved care and treatment protocols, to help patients get the best care
- Invested in research and partnerships to advance new treatments, like rituximab, abatacept, baricitinib, and others
You are the power behind this progress, and we are so grateful.
With your help, we will see even more breakthroughs in the coming year.